Animal Testing Cell Based Assays Pharmacokinetics 
Drug Target Review
JULY 7, 2025
Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials. NHP-C cardiomyocytes offer a more predictive and ethical platform, especially for drugs intended to advance from animal testing to first-in-human trials. Bailey J, et al.
FDA Law Blog: Drug Discovery
FEBRUARY 2, 2023
In effect, the revisions to the FD&C Act and the PHS Act are designed to encourage the use of alternatives to animal testing not eliminate animal testing in drug development. adequate to justify the proposed clinical testing.” The pre-existing statutory language did not require animal testing.
Expert insights. Personalized for you.
Let's personalize your content